Abstract Although estrogen receptor alpha (ERa) and insulin-like growth factor (IGF) signaling are important for normal mammary development and breast cancer, crosstalk between these pathways, particularly at the level of transcription, remains poorly understood. We performed microarray analysis on MCF-7 breast cancer cells treated with estradiol (E2) or IGF-I for 3 or 24 h. IGF-I regulated mRNA of five to tenfold more genes than E2, and many genes were co-regulated by both ligands. Importantly, expression of these co-regulated genes correlated with poor prognosis of human breast cancer. Closer examination revealed enrichment of repressed transcripts. Interestingly, a number of potential tumor suppressors, for example, B-cell linker (BLNK), were down-regulated by IGF-I and E2. Analysis of three down-regulated genes showed that E2-mediated repression occurred independently of IGF-IR, and IGF-I-mediated repression occurred independently of ERa. However, repression by IGF-I or E2 required common kinases, such as PI3K and MEK, suggesting downstream convergence of the two pathways. In conclusion, E2 and IGF-I co-regulate a set of genes that affect breast cancer outcome. There is enrichment of repressed transcripts, and, for some genes, the down-regulation is independent at the receptor level. This may be important clinically, as tumors with active ERa and IGF-IR signaling may require co-targeting of both pathways.
Introduction
Breast cancer is a heterogeneous disease that is characterized by abnormal growth and survival of the epithelial cells of the breast. Steroid hormones, such as estrogen, and growth factors, such as insulin-like growth factor (IGF), can be major drivers of the disease, as both of these signaling pathways are highly mitogenic and anti-apoptotic.
The effects of 17-b-estradiol (E2) are mediated through the estrogen receptors (ER) a and b. Both receptors are modular in structure with several distinct domains, including an amino-terminally located ligand-independent transcriptional activation function (AF-1) domain, a DNA-binding domain (DBD), a hinge region, and a liganddependent AF-2 domain. In the classical mode of action, ligand binding results in a conformational change of ERa, which then allows it to directly interact with DNA at sequence-specific estrogen response elements (EREs). However, other modes of estrogen signaling have been described, including indirect DNA binding through interactions with other transcription factors, ligand-independent activation of the receptor by kinase cascades, and membrane-associated receptor signaling [1] .
The IGF family consists of two ligands (IGF-I and IGF-II), two receptors (IGF-IR and IGF-IIR), and several IGF binding proteins [2] . Ligand binding induces a conformational change in the receptor, resulting in activation of the intrinsic tyrosine kinase of the cytoplasmic domain of IGF-IR [3] . Subsequent recruitment and phosphorylation of adaptor proteins, most notably the insulin receptor substrate (IRS) family of adaptors, transduces the intracellular signal. Activation of downstream kinases, such as MAPK and PI3K, are largely responsible for the proliferative and anti-apoptotic nature of active IGF signaling.
Interactions between estrogen and IGF action have been found in several tissues, including the uterus and mammary gland. In the uterus, studies have shown that estrogen treatment rapidly activates IGF-IR in an IGF-I-dependent manner [4, 5] . Conversely, IGF-I stimulation can result in phosphorylation and activation of ERa [6] . Furthermore, this same study showed that IGF-I fails to stimulate proliferation in the uterus of the ERa knockout mouse. A recent microarray study aimed at understanding the global transcriptional changes in the mouse uterus found that most of the gene regulation elicited by E2 also occurred after growth factor treatment [7] .
Cross-talk between estrogen and IGF has also been documented in the mammary gland. In fact, the ERa knockout mouse [8] and the IGF-I knockout mouse [9] exhibit a similar defect in which elongation of the mammary ductal tree fails to occur. Furthermore, hypophysectomized and ovariectomized animals do not respond to estrogen treatment unless they also receive IGF-I [10] . In addition, IGF signaling components are hormonally regulated in the mouse mammary gland [11, 12] .
In addition to their cooperative roles in normal mammary gland development, interaction between these two pathways has also been described in breast cancer. For example, there is a correlation between IGF-IR/IRS-1 and ERa in breast cancer specimens [11] , and this is likely due to the fact that components of the IGF system are estrogenregulated. However, cross-talk occurs in both directions as active IGF signaling can phosphorylate ERa and enhance its activity [13] . Given the close interaction between these two pathways, it is not surprising that this cross-talk manifests itself at the clinical level as well. For example, treatment of breast cancer patients with anti-estrogens has been shown to reduce serum IGF-I levels [14] . This is important since high serum IGF-I levels predict an increased risk of breast cancer [15] . Furthermore, hyperactive IGF signaling has been associated with resistance to endocrine therapies [2] .
Despite the extensive data showing the importance of interaction between these pathways for both normal mammary development and breast cancer pathogenesis, cross-talk between these pathways, particularly at the level of gene transcription, remains poorly understood. In order to address this problem, we performed microarray analysis on MCF-7 breast cancer cells treated with E2 or IGF-I. We discovered that many genes are regulated by both ligands, and, interestingly, that there is enrichment of repressed targets within the co-regulated group. One of the most repressed target genes identified in our array was B-cell linker (BLNK). BLNK protein is a well-described tumor suppressor in lymphoma [16] and may also inhibit growth in breast cancer.
Materials and methods
Cell culture MCF-7 human breast cancer cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Cellgro) supplemented with 5% characterized fetal bovine serum (HyClone), 100 IU/ml penicillin, 100 lg/ml streptomycin, and 0.25 lg/ml amphotericin B (antibiotics and antimycotic from Cellgro). Prior to ligand treatment for all experiments, cells were starved under serum-free conditions for at least one day. Serum-free medium (SFM) consists of phenol red-free improved minimal essential medium (IMEM; Invitrogen), 100 IU/ml penicillin, 100 lg/ml streptomycin, 0.25 lg/ml amphotericin B, 10 mM HEPES (Invitrogen), 1 lg/ml transferrin (Sigma), and 1 lg/ml fibronectin (BD Biosciences). For ligand stimulation, cells were treated with 10 nM 17-b-estradiol (E2; Sigma) and 100 ng/ml insulin-like growth factor I (IGF-I; Novozymes), either alone or in combination. For untreated control samples, cells were simply maintained in SFM. In some experiments, cells were pre-treated for 30 min with a chemical inhibitor prior to ligand stimulation. Inhibitors used include the IGF-IR antagonist BMS-536924 (1 lM; Bristol-Myers Squibb), the pure antiestrogen ICI 182780 (100nM; Sigma), the PI3K inhibitor LY-294002 (20 lM; Calbiochem), the MEK inhibitor U0126 (10 lM; Calbiochem), and the PKC antagonist Gö 6983 (0.25 lM; Calbiochem).
RNA extraction and qRT-PCR
Total RNA was isolated using the RNeasy RNA isolation kit (Qiagen) as recommended by the supplier. Triplicate RNA samples were prepared for each treatment group. RNA was reverse transcribed using SuperScript II reverse transcriptase (Invitrogen) in accordance with manufacturer's instructions. The PCR reaction was then carried out on an ABI 7500 fast real-time thermocycler (Applied Biosystems) using the SYBR green master mix (Applied Biosystems) and 150 nM each of both the forward and reverse primers. The cycling conditions were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 30 s. Primer Express 3.0 software (Applied Biosystems) was used to design all of the primers. The sequences of the primers used are listed in the supplementary material Table S1 . The fold change for each gene was calculated using the cycle threshold (DDC T ) method as previously described [17] , and data are represented as ligand-mediated fold change over SFM, unless otherwise stated. For each sample, real-time quantitative reverse transcription-PCRs (qRT-PCRs) were done in triplicate for both the genes of interest and the reference gene (b-actin) to normalize for input cDNA.
Microarray analysis MCF-7 cells were plated in 10 cm dishes and then switched to SFM on the next day. Following overnight starvation, cells were treated in triplicate with either E2 (10 nM) or IGF-I (50 ng/ml) for 3 or 24 h. Control samples were maintained in SFM and left untreated. Cells were lysed, and total RNA was isolated using the RNeasy kit (Qiagen) according to the manufacturer's instructions. cDNA synthesis, cRNA labeling, and array hybridization to Affymetrix HG U133A 2.0 gene chips were performed as previously described [18] . Arrays were processed and normalized using the dChip software (http://biosun1. harvard.edu/complab/dchip/) [19] . Data analysis was carried out by the Biostatistics and Bioinformatics Core of the Lester and Sue Smith Breast Center at Baylor College of Medicine. Expression estimation and search for differentially expressed genes were performed using Array Analyzer software (http://www.tibco.com/). Expression values for all chips were estimated using the GCRMA model. ANOVA with contrasts was performed separately for the 3 and 24 h treatment groups. The two factors in ANOVA were IGF and SFM. The criterion for differentially expressed genes was FDR = 0.05 [20] . Quality control was done with dChip and Array Analyzer. GO term analysis and correlation of gene signatures with cancer patient outcome were carried out as previously described [21] .
Immunoblotting
Proteins were resolved on 8% SDS-PAGE and transferred to nitrocellulose. The membrane was blocked in 5% milk dissolved in phosphate-buffered saline ? 0.1% Tween 20 (PBST) for 1 h at room temperature. Primary antibodies used include anti-BLNK (Santa Cruz Biotechnology; sc-8003) and anti-b-actin (Sigma; A5441). The BLNK antibody was diluted 1:500 in PBST ? 5% milk and incubated overnight at 4°C. The b-actin antibody was diluted 1:5000 in PBST ? 5% milk and incubated overnight at 4°C. After washing thrice for 5 min with PBST, the membranes were incubated with anti-mouse or anti-rabbit secondary antibodies conjugated to either IRDye700 or IRDye800 (Rockland) for 1 h at room temperature. Secondary antibodies were diluted 1:5000 in PBST ? 5% milk. After incubation, membranes were washed three times for 5 min with PBST, and the signal was visualized using the Odyssey imaging system (Li-Cor Biosciences).
siRNA and MTS assay MCF-7 cells were plated in 10 cm dishes and *48 h later, cells were transfected with 50 nM small interfering RNA (siRNA) using DharmaFECT1 (Thermo Fisher Scientific). The siRNAs used were as follows: siGENOME non-targeting siRNA #2 (Dharmacon) and BLNK (Sigma; 5 0 -GAU UCCAAACAACCAUAUA-3 0 ). The next day, cells were split and re-plated in a 96-well plate. Cells were incubated in medium containing either 5% fetal bovine serum (FBS) or 5% charcoal-stripped FBS. Cell growth was assessed by MTS assay (Promega) on days 0, 1, 2, and 4. The experiment was performed with biological quintuplicates.
Results
Microarray analysis reveals a number of genes that are regulated by both E2 and IGF-I in MCF-7 cells
We performed microarray analysis on MCF-7 breast cancer cells, which express high levels of both ERa and IGF-IR, following treatment with either E2 (10nM) or IGF-I (50 ng/ ml) for 3 or 24 h (Fig. 1a) . RNA was isolated, and gene expression array profiles were analyzed. The data have been deposited in NCBI's Gene Expression Omnibus [22] and are accessible through GEO Series accession number GSE26834 (http://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE26834). Using a fold change [1.5 and a P value \0.01, *3,051 probesets were found to be significantly altered upon stimulation with IGF-I at the 3 h time point. Approximately tenfold fewer probesets (297) were found to be either up-or down-regulated following treatment with E2 for 3 h. A similar pattern was observed after 24 h of treatment. IGF-I significantly altered about five times as many probesets (3,659) as E2 (649). Representative gene lists can be found in Tables 1 and 2 .
While E2 and IGF-I independently regulate a number of genes, we also found significant and extensive overlap between target genes regulated by both ligands. For example, of the 297 estrogen-regulated probesets at the 3 h time point, 183 overlapped with the IGF-I-regulated probesets as represented in a Venn diagram (Fig. 1b) . The overlap between estrogen-and IGF-I-regulated genes is highly statistically significant (P \ 0.001) (X 2 , with continuity correction in SPLUS). Furthermore, the overlap is even more striking after 24 h of ligand stimulation with 454 of the 649 estrogen-regulated genes also being regulated by IGF-I. We performed quantitative real-time RT-PCR to verify genes within each section of the Venn diagrams, and representative target genes are shown (Fig. 1c) .
In addition, we performed gene ontology (GO) analysis on genes that were found to be either induced by both E2 and IGF-I or repressed by both ligands at the 3 and 24 h time points. Genes induced at both time points were enriched for DNA metabolism and replication. For example, at the 3 h time point, 16 genes fell into one of these two GO categories. At the 24 h time point, 29 genes were associated with these two groups. Taking into account the total number of genes within each population, these represent two of the most statistically significant categories that we identified (P \ 0.00001). In contrast, GO terms enriched for repressed genes at the 3 and 24 h time points were more distinct. At the 3 h time point, genes repressed by both E2 and IGF-I were generally enriched for development and embryonic specification (P \ 0.005), while at 24 h there was enrichment of chromosome organization and nucleosome assembly (P \ 0.0001). A more detailed description of the GO analysis can be found in the supplemental material (Fig. S1 ). Expression of E2 and IGF-I co-regulated genes is correlated with poor prognosis of human breast cancer
In order to determine if the E2 and IGF-I co-regulated genes were associated with any clinical significance, we examined whether they had any prognostic value in human breast cancer. We defined an ''E2-IGF co-regulated gene activation score'' for a given tumor as the Pearson correlation between the E2-IGF co-regulated genes at 24 h (by using 1 for up and -1 for down) and the gene expression values of the 295 tumors from the publicly available van de Vijver dataset [23] . Due to the fact that we were looking at estrogen-regulated genes (and also due to the fact that ERanegative tumors have a poor prognosis), we focused solely on the 226 ERa-positive tumors. Tumors that showed a positive Pearson's correlation (P \ 0.01) were then classified as having an ''activated'' E2-IGF co-regulated signature (i.e., significant correlation, P \ 0.01, to the pattern of up-and down-regulation by E2 and IGF-I observed in vitro). Tumors that had a significant anti-correlation (P \ 0.01) had a ''deactivated'' signature. Finally, those that showed no significant association (P [ 0.01) were termed ''intermediate''. Using this classification, KaplanMeier curves showed significant differences in time to metastasis among the three groups (log rank P \ 1E-6), with patients in the activated group having a shorter time to metastasis compared to those patients in either the deactivated or intermediate groups (Fig. 2a) . Importantly, the effect on prognosis was not simply due to the fact that estrogen and IGF-I induce proliferative genes (proliferation is a known poor prognostic marker in breast cancer), as removal of genes that were either annotated as ''cell cycle'' by gene ontology (GO) analysis or were experimentally found to be correlated with cell cycle progression [24] had very little effect on the Kaplan-Meier analysis (log-rank P = 1.7E-06; Fig. S2 in supplemental material) . In addition, we sought to determine if the E2-IGF-I co-regulated gene signature correlated with a particular subtype of ERa-positive tumors. Using the van de Vijver dataset [23] , we found that *25% of the tumors had an activated E2-IGF-I co-regulated gene expression signature ( Fig. 2b ; denoted by black box). That is, genes induced/ repressed by E2 and IGF-I in MCF-7 cells were similarly expressed in these tumors. Tumors with this activated co-regulated gene signature correlated with the luminal B subtype of ERa-positive breast cancers, which has a worse prognosis than its luminal A counterpart [25] . Interestingly, tumors with a deactivated signature were found to correlate with luminal A disease.
Genes that are co-regulated by E2 and IGF-I are enriched for repressed targets
We identified genes that were either induced by E2 at both 3 and 24 h or repressed by E2 at both time points. When we used the microarray data to examine the expression level of these genes in response to IGF-I treatment, we found that the overlap of genes within the repressed group was more pronounced (Fig. 3a) .
We expanded on this initial observation by looking at patterns of induction and repression specifically within the co-regulated group of genes (P \ 0.05; fold [ 1.1 for induction, fold \ 0.9 for repression) and noticed enrichment for repressed targets. For example, at the 3 h time point, 51% of the 183 co-regulated probesets were repressed by both E2 and IGF-I (Fig. 3b) . This is in contrast to the only 30% of probesets that were induced by both E2 and IGF-I. The least abundant patterns of regulation were those patterns in which E2 and IGF-I had opposite effects on target genes; only 17% of the probesets at the 3 h time point were induced by E2 but repressed by IGF-I, and only 2% were repressed by E2 but induced by IGF-I at this time. A similar pattern was observed after 24 h of ligand treatment.
Many of the co-regulated genes identified in our study may be key targets that estrogen and IGF-I use to mediate cancer progression. Given that the list of co-regulated genes is enriched for repressed targets, it is not surprising that there are a number of potential tumor suppressors that (Fig. 3c) . BLNK, SOCS2, and NR3C1 were all strongly repressed by both ligands at 3 and 24 h. ING4 was strongly repressed by IGF-I at both time points, but the E2-mediated repression was prominent only at the 24 h time point. BIK mRNA was reduced by *40% by E2 and IGF-I following 3 h of treatment. At 24 h, the E2-mediated repression was much prominent than the IGF-I-mediated repression of BIK. Fig. 3 Enrichment of repressed targets within the E2/IGF-I coregulated gene set. a Genes found to be induced by E2 at both 3 h and 24 h or repressed by E2 at both time points were identified. Microarray data was then used to examine expression of these genes in response to IGF-I treatment followed by examination of overlap between E2 and IGF-I regulation of targets within the induced and repressed groups. b Probe sets within the co-regulated group of genes (P \ 0.05; fold [ 1.1 for induction, fold \ 0.9 for repression) were analyzed at both 3 and 24 h and divided into one of four groupsinduced by both E2 and IGF-I, repressed by both ligands, induced by E2 but repressed by IGF-I, and repressed by E2 but induced by IGF-I. : = induced, ; = repressed. c qRT-PCR was used to calculate relative mRNA expression as ligand-mediated fold change compared to the untreated SFM control. MCF-7 cells were starved overnight in SFM and then treated with either E2 (10 nM) or IGF-I (100 ng/ml) for 3 or 24 h. The data are an average of three replicates ? SEM. A t-test analysis was performed in which the E2 and IGF-I treatment groups at each time point were individually compared to the SFM control group at that same time point (*P \ 0.05) E2-mediated repression of tumor suppressor genes is independent of IGF-IR and IGF-I-mediated repression is independent of ERa, but both require common downstream kinases To determine the importance of ERa and IGF-IR in the repression of co-regulated target genes, we pre-treated MCF-7 cells with or without the anti-estrogen ICI 182780 (100 nM) or with a small molecule inhibitor of IGF-IR (BMS-536924, 1 lM). Following 30 min of pre-treatment, cells were stimulated with E2 (10 nM) or IGF-I (100 ng/ml) for 3 or 24 h. Blockade of ERa by ICI 182780 (ICI) dramatically reversed estrogen-mediated repression of BLNK, SOCS2, and CCNG2 at all time points (Figs. 4a, b) . Surprisingly, ICI had little or no effect on the IGF-I-mediated repression of these same genes. Similarly, the anti-IGF-IR inhibitor BMS-536924 (BMS) was able to completely reverse IGF-I-mediated repression of all genes, but it had essentially no effect on estrogen-mediated repression. Further investigation is needed to determine if this independence is specific to the set of genes that we have chosen to study (e.g., maximal repression). RNA was isolated and qRT-PCR was performed. The data are an average of three replicates ? SEM. A t-test analysis was performed in which the E2 and IGF-I treatment groups in the absence of inhibitor were individually compared to the SFM/no inhibitor control group (*P \ 0.05). t test analyses were also performed comparing E2/BMS and IGF-I/BMS to SFM/BMS, and E2/ICI and IGF-I/ICI to SFM/ICI (*P \ 0.05). c MCF-7 cells were starved overnight in SFM and then pre-treated for 30 min with either BMS (1 lM), ICI (100 nM), or the combination of BMS ? ICI. Cells were then simultaneously treated with E2 ? IGF-I for 3 h. RNA was isolated and qRT-PCR was performed. The data are an average of three replicates ? SEM. A t-test analysis was performed in which the E2 ? IGF-I group was compared to the SFM group exposed to the same inhibitor conditions (*P \ 0.05). To build upon this initial observation of receptor independence, we examined the effect of dual ERa/IGF-IR blockade on target gene repression (Fig. 4c) . In the absence of any inhibitor, combined treatment of E2 ? IGF-I strongly repressed BLNK. This repression could only be partially relieved when ERa or IGF-IR alone was blocked. In order to fully restore BLNK levels back to basal and fully abrogate the E2-and IGF-I-mediated repression, combined blockade of ERa and IGF-IR had to be administered.
To determine if this independence existed downstream of the receptor level as well, MCF-7 cells were treated with E2 and IGF-I in the presence of various inhibitors, including antagonists of PI3K (LY-294002; 20 lM), MEK (U0126; 10 lM), and PKC (Gö 6983; 0.25 lM). In the absence of inhibitor, E2 and IGF-I strongly repressed BLNK mRNA (Fig. 4d) . Blockade of PI3K almost completely relieved the E2-mediated repression and significantly impeded the ability of both IGF-I alone and E2 ? IGF-I to repress BLNK. Blockade of MEK partially abrogated BLNK repression under all treatment conditions but was unable to restore BLNK levels to those seen under basal conditions. Inhibition of PKC had no effect on either the E2-or IGF-I-mediated BLNK repression, suggesting that PKC does not lie downstream of estrogen or IGF signaling in repression of this particular target gene. Clearly, these experiments do not rule out the possibility that other kinases may be involved in the estrogen-and IGF-I-mediated repression of BLNK.
BLNK inhibits MCF-7 cell growth
BLNK was one of the top genes identified in our microarray study to be strongly repressed by both E2 and IGF-I. However, not much is known about the role of BLNK in breast cancer. If BLNK regulation by estrogen and IGF-I is important for breast cancer cell biology, then the ligandmediated reduction in mRNA transcript should be reflected at the protein level as well. To determine if E2 and IGF-I could lower BLNK protein levels, we treated MCF-7 cells with E2 (10 nM), IGF-I (100 ng/ml), or the combination of both ligands for 48 h (Fig. 5a ). Control cells, maintained in SFM, had the highest level of BLNK expression. Treatment of cells with either E2 or IGF-I resulted in a decrease in BLNK protein. Interestingly, the simultaneous administration of E2 ? IGF-I resulted in a complete loss of BLNK protein. These data support the idea that both estrogen and IGF signaling repress BLNK protein levels via distinct mechanisms that can cooperate in an additive manner.
Given its potential role as a tumor suppressor, we wanted to investigate the function of BLNK and its effect on MCF-7 cell biology. We decided to mimic the E2-and IGF-I-mediated repression of BLNK by knocking down BLNK expression using transient siRNA transfection in MCF-7 cells. Cells cultured in charcoal-stripped FBS and transfected with non-specific siRNA (Fig. 5b, top bottom panel, dashed line) did not enhance growth compared to cells transfected with the non-specific siRNA control (Fig. 5b, bottom panel, solid line) . This may be due to the fact that steroid hormones and growth factors are present in full serum. BLNK levels may already be extremely low due to repression by these ligands, and siRNA may be unable to further reduce BLNK levels. As proof of principle of this concept, we cultured MCF-7 cells either in 5% complete fetal bovine serum (FBS) or 5% charcoalstripped FBS (CSS) for 72 h (Fig. 5b) . While BLNK protein was undetectable in cells cultured in FBS, cells cultured in CSS had appreciable BLNK protein expression. Furthermore, and in line with this train of thought, cells cultured in medium devoid of any serum had the highest BLNK expression levels (data not shown). Thus, our data show that BLNK is dynamically regulated by E2 and IGF-I and that loss of BLNK may confer a growth advantage.
Discussion
Here, we report a novel microarray-based examination of estrogen and IGF-I action in MCF-7 breast cancer cells. Under serum-free conditions, IGF-I is a much more potent regulator of transcription than is E2. In fact, at the 3 h time point, IGF-I significantly regulated about 10 times as many probe sets as did E2. This is likely due to the extensive and pleiotropic downstream effects of IGF-I, whereby activation of the receptor can lead to multiple phosphorylation cascades. Previous microarray studies examining effects of IGF-I have been published [26] [27] [28] , and, importantly, we found significant overlap between genes regulated by exogenously administered IGF-I in our study and genes that were found to be regulated in other studies as well. There have also been many studies examining the global effects of estrogen on gene expression [29] [30] [31] [32] [33] . Interestingly, data have shown that ERa, classically described as an activator, can repress at least as many genes as it induces [34] . This is exactly what we found in our microarray study as well. In addition, comparison of the estrogen-regulated transcripts from our array to the numerous previously published microarray studies showed extensive overlap. Despite this fact, a number of genes shown to be regulated by E2 in other microarray studies were not significantly regulated by E2 in our array. This may be the result of starving our cells in SFM, in contrast to the more common starvation of cells in medium containing charcoal/dextran-treated fetal bovine serum. This does not come as a complete surprise given the previous work in the field. For example, estrogen-mediated induction of progesterone receptor (PR), a classical ERa target gene, does not occur when cells are in medium containing serum concentrations below 1% [35] . However, estrogen-mediated activation of PR could be restored by either increasing serum concentrations or supplementing the medium with insulin or IGF-I. Our data presented here lends support to and builds upon this idea that a large fraction of ERa transcriptional activity is dependent on ERa interaction with other cellular pathways. We found that estrogen and IGF-I co-regulate a large number of target genes, and that these genes are biologically important. That is, human breast tumors showing the same pattern of gene expression to the pattern we observed in MCF-7 cells following stimulation with E2 or IGF-I had a significantly worse prognosis. Furthermore, these tumors with the activated co-regulated gene signature correlated with the luminal B subtype of ERa-positive breast cancers. This is important since some of the genes we identified in our array may be key targets that E2 and IGF-I use to elicit their biological response. Taking this into consideration, and given the fact that there is enrichment for repressed genes within our data set, it is not surprising that several of the genes have been previously described as tumor suppressors and growth inhibitors. Many studies focus on how E2 and IGF-I ''turn on'' genes to promote tumorigenesis. However, the data we provide here highlight the fact that what these ligands deactivate may be just as important, if not more important, as what they activate in terms of promoting carcinogenesis.
For the target genes we examined, we found that E2 and IGF-I use common downstream kinases, including MEK and PI3K, to elicit repression. This is distinct from what occurs upstream, as we found that repression at the level of ERa and IGF-IR occurs independently. Initially, this may be somewhat surprising given the previous data that we and others have generated indicating positive interaction between these two signaling pathways. For example, IGF-Imediated induction of cyclin D1 was shown to be dependent on ERa expression [36] . In addition, E2-mediated induction of pS2 was significantly enhanced by the addition of IGF-I [37] . Despite these findings, our data argue that there may be multiple ways in which E2 and IGF-I can cooperate to repress target genes and that it does not have to occur in a strictly linear pathway. In total, we examined 10 genes (Figs. 4a, b and data not shown) that were either repressed or induced by E2 and IGF-I in the presence or absence of either BMS or ICI. For these 10 genes, we found that the estrogen-mediated regulation of transcripts did not rely on IGF-IR, and the IGF-I-mediated regulation occurred independently of ERa. Further investigation is needed to determine the nature of this independence, but it should be noted that this is not the first time that such results have been reported. A previous study using microarray-based evaluation of ERa/growth factor cross-talk in vivo in the mouse uterus revealed that a number of genes are regulated by IGF-I in an ERa-independent manner [7] .
One of the top targets found in our array to be repressed by both E2 and IGF-I was BLNK, a well-documented tumor suppressor in cancer of the immune system. BLNK knockout mice spontaneously develop lymphoma [16] . In addition, 50% of childhood pre-B cell acute lymphoblastic leukemias display decreased BLNK expression [38] . Although not much is known about BLNK's role in breast cancer, our data suggest that BLNK regulates growth of MCF-7 cells as well. In B cells of the immune system, BLNK, which acts as a scaffolding protein [39] , has been shown to inhibit multiple proliferative pathways, including the JAK/STAT pathway [40] and components of the MAPK cascade [41] . Through this inhibition, BLNK promotes induction of p27 kip1 , cell cycle arrest, and apoptosis. It will be interesting to determine if BLNK functions in a similar fashion in breast cancer cells. One interesting observation we made concerns the dynamic regulation of BLNK protein levels in medium devoid of serum or containing either full serum or CSS. BLNK protein was highest in serum-free conditions, somewhat lower in CSS, and barely detectable in full serum. It is likely that the differential response of MCF-7 cell growth that we observed in response to siRNA-mediated knockdown in full serum compared to CSS was due to the aforementioned regulation of BLNK in different culture conditions. Although the experiment was not performed, one could speculate that BLNK knockdown in MCF-7 cells cultured in SFM would have the most dramatic effect on cell growth. The increased repression of BLNK protein seen with full serum compared to CSS correlates with the total loss of BLNK protein following simultaneous administration of E2 ? IGF. Importantly, some BLNK protein remained detectable after treatment with either E2 or IGF-I alone.
In summary, our study provides evidence that E2 and IGF-I repress a large number of common target genes. For many of these gene transcripts, the E2-mediated repression occurs independently of IGF-IR, and the IGF-I-mediated repression does not rely on ERa, emphasizing the independent and distinct nature of target gene repression. This fact may be clinically relevant. For example, if BLNK or other target genes are key suppressors of tumorigenesis, then one would reason that maintaining BLNK levels would be effective in limiting disease progression. Given that estrogen and IGF signaling can independently repress BLNK, it stands to argue that tumors with active estrogen and IGF signaling, for example, luminal B breast tumors, would have extremely low BLNK expression. Furthermore, in order to completely restore BLNK levels, one would have to inhibit both ERa and IGF signaling pathways. This lends support to the idea that there is likely a subset of breast tumors that would benefit from co-targeted therapy of both the ERa and IGF signaling pathways. This idea has been tested both pre-clinically and in several ongoing clinical trials. In conclusion, the data we have presented here provide further support for these types of trials and highlight the genome-wide effects of E2 and IGF-I action in breast cancer cells. Importantly, there is enrichment of transcriptional repression within the co-regulated gene set, and the down-regulation is independent at the receptor level.
